tyrosine kinase inhibitors trang 4 tải miễn phí từ TAILIEUCHUNG

"tyrosine kinase inhibitors" trang 4 - tải miễn phí từ Tailieuchung

Efficacy and safety of apatinib in the treatment of osteosarcoma: A single-arm meta-analysis among Chinese patients

Efficacy and safety of apatinib in the treatment of osteosarcoma: A single-arm meta-analysis among Chinese patients

11 38 1

Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment

Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment

7 19 1

ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial–mesenchymal transition

ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial–mesenchymal transition

11 20 1

Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: A propensity-matched retrospective study

Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: A propensity-matched retrospective study

10 12 1

Propofol enhances BCR-ABL TKIs’ inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression

Propofol enhances BCR-ABL TKIs’ inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression

8 13 1

Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: A network meta-analysis

Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: A network meta-analysis

11 7 1

A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor

A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor

8 8 1

Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first line tyrosine kinase inhibitors: Brain metastasis and de novo T790M matters

Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first line tyrosine kinase inhibitors: Brain metastasis and de novo T790M matters

11 10 1

Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalinfixed paraffin-embedded tissue of nonsmall cell lung cancer

Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalinfixed paraffin-embedded tissue of nonsmall cell lung cancer

10 71 0

A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: Treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)

A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: Treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)

6 82 0

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

9 59 0

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: Predictors and pitfalls

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: Predictors and pitfalls

8 54 0

The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: A case report

The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: A case report

4 51 0

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: A retrospective study

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: A retrospective study

10 52 0

Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs

Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs

9 75 1

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma

7 25 1

Chemotherapy-induced Takotsubo cardiomyopathy, a case report and review of the literature

Chemotherapy-induced Takotsubo cardiomyopathy, a case report and review of the literature

5 22 1

Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: Initial experience of molecularly targeted therapy

Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: Initial experience of molecularly targeted therapy

9 44 1

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

10 31 1

Randomized phase II study of paclitaxel/ carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapynaïve non-small cell lung cancer in a clinically selected population excluding patients with nonsmoking adenocarcinoma or mutated EGFR

Randomized phase II study of paclitaxel/ carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapynaïve non-small cell lung cancer in a clinically selected population excluding patients with nonsmoking adenocarcinoma or mutated EGFR

7 28 1

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.